Biologics Safety Testing Market Size, Share and Growth Outlook, 2026

Biologics Safety Testing Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Biologics Safety Testing Market size is forecast to increase from $5.35 Billion in 2026 to $12.87 Billion in 2034 at a CAGR of 11.6% between 2026 and 2034.

The Biologics Safety Testing market report provides detailed analysis and outlook of Biologics Safety Testing segments including By Product & Service (Services, Consumables, Instruments), By Test Type (Endotoxin Tests, Sterility Tests, Mycoplasma Tests, Bioburden Tests, Viral Safety Tests, Residual Host-Cell Protein and DNA Detection Tests), By Application (Monoclonal Antibodies, Vaccines Development & Manufacturing, Cellular and Gene Therapy Products, Blood & Blood Products), By End-User (Pharmaceutical & Biotechnology Companies, Contract Development and Manufacturing Organizations, Academic & Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Biologics Safety Testing Industry Overview

Critical Role of Safety Testing in Biologic Product Development

The biologics safety testing industry remains a fundamental component of biologic drug development, supporting the safety, purity, and quality assessment of monoclonal antibodies, recombinant proteins, vaccines, cell therapies, and viral vector-based therapeutics. Increasing regulatory expectations, growing complexity of biologic products, and the expansion of advanced therapeutic modalities are driving demand for sophisticated analytical testing services. Safety testing providers are investing in advanced technologies, expanded laboratory capacity, and high-sensitivity analytical methods to meet the evolving requirements of pharmaceutical and biotechnology companies. The industry is increasingly focused on improving testing accuracy, accelerating release timelines, and ensuring regulatory compliance throughout product development and commercialization.

Expansion of Viral Clearance and Cell Line Characterization Services

A significant industry development has been the expansion of analytical capabilities supporting biologic safety evaluation. Charles River Laboratories announced the expansion of its advanced facility in Cologne, Germany, with substantial upgrades designed to increase capacity for viral clearance studies and cell line characterization services. These testing activities are critical for ensuring the safety of monoclonal antibodies and viral vector-based therapies by demonstrating the effective removal or inactivation of potential viral contaminants during manufacturing. The investment reflects growing industry demand for specialized safety testing infrastructure capable of supporting the increasing volume of biologic and advanced therapy development programs.

Rapid Microbiological Methods Accelerating Product Release

Biopharmaceutical manufacturers are increasingly adopting Rapid Microbiological Methods (RMM) to improve testing efficiency and strengthen supply chain responsiveness. Major industry participants, including Lonza, are accelerating implementation of rapid sterility testing systems that utilize automated microbial identification technologies. These platforms are designed to replace traditional culture-based sterility methods that can require up to fourteen days for completion. By significantly reducing biologic product release timelines, rapid microbiological methods support faster manufacturing cycles, improved inventory management, and greater operational agility. The transition toward automated sterility testing reflects broader industry efforts to modernize quality control processes while maintaining rigorous safety standards.

Regulatory Focus on Host-Cell Protein Detection Driving Analytical Innovation

Regulatory agencies are placing increased emphasis on advanced impurity testing methodologies for next-generation biologic products. The FDA and EMA have intensified scrutiny regarding host-cell protein detection in high-concentration biologic formulations, recognizing the potential impact of residual impurities on product safety and efficacy. Regulatory guidance issued during 2026 highlights the importance of adopting highly sensitive mass spectrometry-based analytical methods rather than relying solely on traditional ELISA techniques. These advanced detection approaches provide more comprehensive characterization of host-cell protein contaminants and improve confidence in product purity assessments. As biologic formulations become increasingly complex, manufacturers and testing laboratories are investing in high-resolution analytical technologies to meet evolving regulatory expectations and ensure the safety of modern biologic therapies.

Biologics Safety Testing Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Biologics Safety Testing market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Thermo Fisher Scientific Inc., Charles River Laboratories International, Inc., Merck KGaA (MilliporeSigma), Lonza Group AG, Eurofins Scientific SE, bioMérieux SA, SGS SA, Sartorius AG, WuXi AppTec Co., Ltd., Promega Corporation. The Biologics Safety Testing market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Biologics Safety Testing industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Biologics Safety Testing Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Biologics Safety Testing companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Biologics Safety Testing markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Biologics Safety Testing Market Competitive Benchmarking and Company Analysis

Leading companies in Biologics Safety Testing industry include- Thermo Fisher Scientific Inc., Charles River Laboratories International, Inc., Merck KGaA (MilliporeSigma), Lonza Group AG, Eurofins Scientific SE, bioMérieux SA, SGS SA, Sartorius AG, WuXi AppTec Co., Ltd., Promega Corporation. The Biologics Safety Testing market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Biologics Safety Testing Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Biologics Safety Testing market remains one of the strongest-performing segments in the country.
The US Biologics Safety Testing Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Biologics Safety Testing market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Biologics Safety Testing industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Biologics Safety Testing markets

Canada's strong Biologics Safety Testing sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Biologics Safety Testing market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Biologics Safety Testing Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Biologics Safety Testing market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Biologics Safety Testing population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Biologics Safety Testing industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Biologics Safety Testing market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Biologics Safety Testing sales through 2034

France Biologics Safety Testing companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Biologics Safety Testing Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Biologics Safety Testing distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Biologics Safety Testing Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Biologics Safety Testing market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Biologics Safety Testing industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Biologics Safety Testing industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Biologics Safety Testing Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Biologics Safety Testing market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Biologics Safety Testing market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Biologics Safety Testing Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Biologics Safety Testing Market Segmentation

By Product & Service
Services
Consumables
Instruments
By Test Type
Endotoxin Tests
Sterility Tests
Mycoplasma Tests
Bioburden Tests
Viral Safety Tests
Residual Host-Cell Protein and DNA Detection Tests
By Application
Monoclonal Antibodies
Vaccines Development & Manufacturing
Cellular and Gene Therapy Products
Blood & Blood Products
By End-User
Pharmaceutical & Biotechnology Companies
Contract Development and Manufacturing Organizations
Academic & Research Institutes

Top Companies in Biologics Safety Testing Industry

Thermo Fisher Scientific Inc.
Charles River Laboratories International, Inc.
Merck KGaA (MilliporeSigma)
Lonza Group AG
Eurofins Scientific SE
bioMérieux SA
SGS SA
Sartorius AG
WuXi AppTec Co., Ltd.
Promega Corporation

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025